152 results on '"Ost, Piet"'
Search Results
2. Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy.
- Author
-
Mercier, Carole, Billiet, Charlotte, Ost, Piet, Joye, Ines, Meijnders, Paul, Vermeulen, Peter, Dirix, Luc, Verellen, Dirk, and Dirix, Piet
- Subjects
- *
STEREOTACTIC radiotherapy , *LYMPHATIC metastasis , *PROSTATE tumors , *PROGRESSION-free survival , *DISEASE relapse - Abstract
Stereotactic body radiation therapy is increasingly used for oligometastatic disease as well as palliation, but treatment protocols for nonspine bone and nodal metastases are lacking, with a wide variety of schedules applied. A prospective dose-escalation trial was initiated, involving 90 patients, among whom 52 (58%) had primary prostate tumors, 13 had breast tumors (14%), and 25 (28%) had other primary tumor types. All visible lymph node or nonspine bone oligometastases were treated in 3 consecutive cohorts: 5 × 7.0 Gy, 3 × 10.0 Gy, or 1 × 20.0 Gy. Initial results revealed no dose-limiting toxicity after a median follow-up of 17.2 months. This update provides information on long-term toxicity, local failure (LF), and progression-free survival (PFS). After a median follow-up of 50 months, no new safety signals were observed. Grade 2 toxicity was 13%, 7% and 10% in the respective cohorts (P =.9), without grade 3 to 5 toxicities. LF rates were 9%, 3%, and 6% (P =.5) for the respective treatment groups, with an overall cumulative risk of LF of 7% (95% CI, 2-12) at 4 years. Median PFS was 16.5 months (95% CI, 9.8-21.5), and 4-year PFS was 21% (95% CI, 14-32). Median overall survival across groups was not reached (95% CI, 52.8 – not reached), 4-year OS was 68% (95% CI, 59-78). A subset of patients (23%) remained long-term disease-free, 37% had oligoprogressive disease at first recurrence and 40% developed polymetastatic relapse. The safe and effective use of dose-escalated single-fraction stereotactic body radiation therapy for bone and lymph node metastases is supported by this trial, especially considering patient-convenience and cost-effectiveness. Caution is needed when generalizing these outcomes beyond breast and prostate cancer, given their underrepresentation in our study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Developments in oligometastatic hormone-sensitive prostate cancer.
- Author
-
Tran, Phuoc T. and Ost, Piet
- Subjects
- *
CASTRATION-resistant prostate cancer , *PROSTATE cancer - Abstract
Newer and highly sensitive imaging modalities for prostate cancer cannot be ignored and will be a critical bridge towards a molecular definition of oligometastatic prostate cancer [[11]]. Pasoglou et al. then present some original work using whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligometastatic and polymetastatic prostate cancer and the impact of the initial treatment on metastatic distribution [[13]]. In the modern era with conventional imaging, metastatic prostate cancer as a whole is only a minority of newly diagnosed cases making I synchronous i or de novo oligometastatic prostate cancer an even smaller subset of these men. Nonetheless, this is an exciting and important clinical space where Nicholas Nickols and his group review the existing data evaluating primary tumor therapy for patients with metastatic prostate cancer and describe ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with metastatic prostate cancer [[14]]. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
4. Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.
- Author
-
van den Bergh, Roderick C. N., Ost, Piet, Surcel, Christian, Valerio, Massimo, Fütterer, Jurgen J., Gandaglia, Giorgio, Sooriakumaran, Prasanna, Tilki, Derya, Tsaur, Igor, Ploussard, Guillaume, and the European Association of Urology Working Party on Prostate Cancer (EAU-YAUWP)
- Subjects
- *
CASTRATION-resistant prostate cancer , *GUIDELINES , *CLINICAL trials , *MEDICAL education , *MEDICAL care , *CANCER treatment - Abstract
Purpose: Guidelines and recommendations become increasingly important in clinical urologic practice. This study aims to inform clinicians using guidelines on how to evaluate the quality of the methodology and transparency of these documents.Methods: The guidelines on management of castration-resistant prostate cancer of the American Urology Association, European Association of Urology, National Comprehensive Cancer Network, National Institute for Health and Care Excellence, European Society of Medical Oncology were reviewed using the AGREE-II tool (Appraisal of Guidelines for Research and Evaluation). We reported and compared the domain scores for the domains 1 scope and purpose, 2 stakeholder involvement, 3 rigor of development, 4 clarity of presentation, 5 applicability, and 6 editorial independence (100% indicates highest—best quality score).Results: The domains evaluated highest and with lowest variability were ‘editorial independence’ (92% {88—95%}) and ‘clarity of presentation’ (83% {72-90%}), while the domains with the lowest scores and most variability were ‘stakeholder involvement’ (56% {36-79%}) and ‘applicability’ (40% {30-63%}). Length and extent of detail of guidelines vary considerably, each with its own strengths and limitations and adapted to target users. Standard external review using AGREE criteria may be preferable. A formal search strategy was not performed. Findings may be outdated by guidelines’ updates.Conclusions: Clinicians using practice guidelines need to be aware of the different domains of methodology and transparency used to assess the quality of guidelines contents and recommendations.Patient summary: Urologists increasingly use guidelines for support in evidence-based recommendations in clinical practice. It is very important to know how to assess these documents. This study applies standard criteria to compare the design and background of different available guidelines on prostate cancer no longer responding to hormonal treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
- Author
-
Ost, Piet, Jereczek-Fossa, Barbara Alicja, As, Nicholas Van, Zilli, Thomas, Muacevic, Alexander, Olivier, Kenneth, Henderson, Daniel, Casamassima, Franco, Orecchia, Roberto, Surgo, Alessia, Brown, Lindsay, Tree, Alison, Miralbell, Raymond, and De Meerleer, Gert
- Subjects
- *
PROGRESSION-free survival , *STEREOTACTIC radiotherapy , *PROSTATE cancer patients , *PROSTATE cancer treatment , *CANCER relapse - Abstract
The literature on metastasis-directed therapy for oligometastatic prostate cancer (PCa) recurrence consists of small heterogeneous studies. This study aimed to reduce the heterogeneity by pooling individual patient data from different institutions treating oligometastatic PCa recurrence with stereotactic body radiotherapy (SBRT). We focussed on patients who were treatment naive, with the aim of determining if SBRT could delay disease progression. We included patients with three or fewer metastases. The Kaplan-Meier method was used to estimate distant progression-free survival (DPFS) and local progression-free survival (LPFS). Toxicity was scored using the Common Terminology Criteria for Adverse Events. In total, 163 metastases were treated in 119 patients. The median DPFS was 21 mo (95% confidence interval, 15–26 mo). A lower radiotherapy dose predicted a higher local recurrence rate with a 3-yr LPFS of 79% for patients treated with a biologically effective dose ≤100 Gy versus 99% for patients treated with >100 Gy ( p = 0.01). Seventeen patients (14%) developed toxicity classified as grade 1, and three patients (3%) developed grade 2 toxicity. No grade ≥3 toxicity occurred. These results should serve as a benchmark for future prospective trials. Patient summary This multi-institutional study pools all of the available data on the use of stereotactic body radiotherapy for limited prostate cancer metastases. We concluded that this approach is safe and associated with a prolonged treatment progression-free survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer.
- Author
-
Siva, Shankar, Ost, Piet, Zaorsky, Nicholas, and Staehler, Michael
- Subjects
- *
STEREOTACTIC radiotherapy , *RENAL cancer - Published
- 2021
- Full Text
- View/download PDF
7. Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS.
- Author
-
Ost, Piet, Siva, Shankar, and Zilli, Thomas
- Subjects
- *
ANDROGENS , *IRRADIATION - Published
- 2021
- Full Text
- View/download PDF
8. Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature.
- Author
-
Ost, Piet, Bossi, Alberto, Decaestecker, Karel, De Meerleer, Gert, Giannarini, Gianluca, Karnes, R. Jeffrey, IIIRoach, Mack, and Briganti, Alberto
- Subjects
- *
METASTASIS , *CANCER relapse , *PROSTATE cancer treatment , *SYSTEMATIC reviews , *DIAGNOSIS , *PROSTATE cancer , *CANCER radiotherapy - Abstract
Context The introduction of novel imaging modalities has increased the detection of oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a metastasis-directed therapy (MDT) with surgery or radiotherapy (RT) rather than a systemic approach. Objective To perform a systematic review of MDT for oligometastatic PCa recurrence. Evidence acquisition This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or toxicity or complications of MDT (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. Evidence synthesis Fifteen single-arm case series reporting on a total of 450 patients met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic PCa recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the patients (98%). Nodal, bone, and visceral metastases were treated in 78%, 21%, and 1%, respectively. Patients were treated with either RT (66%) or lymph node dissection (LND) (34%). Adjuvant androgen deprivation was given in 61% of patients ( n = 275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49% of patients ( n = 172). Overall, 51% of patients were progression free 1–3 yr after salvage MDT, with most of them receiving adjuvant treatment. For RT, grade 2 toxicity was observed in 8.5% of patients, with one case of grade 3 toxicity. In the case of LND, 11% and 12% of grade 2 and grade 3 complications, respectively, were reported. Conclusions MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. Patient summary We performed a systematic review to assess complications and outcomes of treating oligometastatic prostate cancer recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?
- Author
-
Fonteyne, Valérie, Ost, Piet, Vanpachtenbeke, Frank, Colman, Roos, Sadeghi, Simin, Villeirs, Geert, Decaestecker, Karel, and De Meerleer, Gert
- Subjects
- *
PROSTATE cancer treatment , *INTENSITY modulated radiotherapy , *LONGITUDINAL method , *PROSTATE cancer patients , *RADIATION doses , *POSTOPERATIVE care - Abstract
Background To define rectal dose volume constraints (DVC) to prevent ⩾grade2 late rectal toxicity (LRT) after intensity modulated radiotherapy (IMRT) for prostate cancer (PC). Material and methods Six hundred thirty-seven PC patients were treated with primary (prostate median dose: 78 Gy) or postoperative (prostatic bed median dose: 74 Gy (adjuvant)–76 Gy (salvage)) IMRT while restricting the rectal dose to 76 Gy, 72 Gy and 74 Gy respectively. The impact of patient characteristics and rectal volume parameters on ⩾grade2 LRT was determined. DVC were defined to estimate the 5% and 10% risk of developing ⩾grade2 LRT. Results The 5-year probability of being free from ⩾grade2 LRT, non-rectal blood loss and persisting symptoms is 88.8% (95% CI: 85.8–91.1%), 93.4% (95% CI: 91.0–95.1%) and 94.3% (95% CI: 92.0–95.9%) respectively. There was no correlation with patient characteristics. All volume parameters, except rectal volume receiving ⩾70 Gy (R70), were significantly correlated with ⩾grade2 LRT. To avoid 10% and 5% risk of ⩾grade2 LRT following DVC were derived: R40, R50, R60 and R65 <64–35%, 52–22%, 38–14% and 5% respectively. Conclusion Applying existing rectal volume constraints resulted in a 5-year estimated risk of developing late ⩾grade2 LRT of 11.2%. New rectal DVC for primary and postoperative IMRT planning of PC patients are proposed. A prospective evaluation is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy.
- Author
-
Van Praet, Charles, Ost, Piet, Lumen, Nicolaas, De Meerleer, Gert, Vandecasteele, Katrien, Villeirs, Geert, Decaestecker, Karel, and Fonteyne, Valérie
- Subjects
- *
POSTOPERATIVE care , *PELVIC radiography , *PROSTATE cancer treatment , *CANCER radiotherapy , *LYMPHATIC metastasis , *PROSTATE cancer patients - Abstract
Abstract: Purpose: To report on toxicity of postoperative high-dose whole-pelvis radiotherapy (WPRT) with androgen deprivation therapy for lymph node metastasized (N1) prostate cancer (PC). To perform a matched-case analysis to compare this toxicity profile to postoperative prostate bed-only radiotherapy (PBRT). Materials and methods: Forty-eight N1-PC patients were referred for WPRT and 239 node-negative patients for PBRT. Patients were matched 1:1 according to pre-treatment demographics, symptoms, treatment and tumor characteristics. Mean dose to the prostate bed was 75Gy (WPRT–PBRT) and 54Gy to the elective nodes (WPRT) in 36 or 37 fractions. End points are genito-urinary (GU) and gastro-intestinal (GI) toxicity. Results: After WPRT, 35% developed grade 2 (G2) and 4% G3 acute GU toxicity. Acute GI toxicity developed in 42% (G2). Late GU toxicity developed in 36% (G2) and 7% (G3). One patient had G4 incontinence. Recuperation occurred in 59%. Late GI toxicity developed in 25% (G2) with 100% recuperation. Incidence of acute and late GI toxicity was higher following WPRT compared to PBRT (p ⩽0.041). GU toxicity was similar. With WPRT mean dose to bladder and rectosigmoid were higher. Conclusions: Postoperative high-dose WPRT comes at the cost of a temporary increase in G2. GI toxicity compared to PBRT because larger volumes of rectosigmoid are irradiated. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
11. Developments in External Beam Radiotherapy for Prostate Cancer.
- Author
-
Lumen, Nicolaas, Ost, Piet, Van Praet, Charles, De Meerleer, Gert, Villeirs, Geert, and Fonteyne, Valerie
- Published
- 2013
- Full Text
- View/download PDF
12. Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT.
- Author
-
Werbrouck, Joke, Ost, Piet, Fonteyne, Valerie, De Meerleer, Gert, De Neve, Wilfried, Bogaert, Evelien, Beels, Laurence, Bacher, Klaus, Vral, Anne, and Thierens, Hubert
- Subjects
- *
PROSTATE cancer treatment , *BIOMARKERS , *CANCER risk factors , *CANCER radiotherapy , *INTENSITY modulated radiotherapy , *RADIATION doses - Abstract
Abstract: Purpose: To investigate whether rotational techniques (Volumetric Modulated Arc Therapy – VMAT) are associated with a higher risk for secondary primary malignancies compared to step-and-shoot Intensity Modulated Radiation Therapy (ss-IMRT). To this end, radiation therapy (RT) induced DNA double-strand-breaks and the resulting chromosomal damage were assessed in peripheral blood T-lymphocytes of prostate cancer (PCa) patients applying γH2AX foci and G0 micronucleus (MN) assays. Methods and materials: The study comprised 33PCa patients. A blood sample was taken before start of therapy and after the 1st and 3rd RT fraction to determine respectively the RT-induced γH2AX foci and MN. The equivalent total body dose (D ETB) was calculated based on treatment planning data. Results: A linear dose response was obtained for γH2AX foci yields versus D ETB while MN showed a linear-quadratic dose response. Patients treated with large volume (LV) VMAT show a significantly higher level of induced γH2AX foci and MN compared to IMRT and small volume (SV) VMAT (p <0.01). Assuming a linear-quadratic relationship, a satisfactory correlation was found between both endpoints (R 2 0.86). Conclusions: Biomarker responses were governed by dose and irradiated volume of normal tissues. No significant differences between IMRT and rotational therapy inherent to the technique itself were observed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
13. High-Dose Adjuvant Radiotherapy After Radical Prostatectomy With or Without Androgen Deprivation Therapy
- Author
-
Ost, Piet, Cozzarini, Cesare, De Meerleer, Gert, Fiorino, Claudio, De Potter, Bruno, Briganti, Alberto, Nagler, Evi V.T., Montorsi, Francesco, Fonteyne, Valérie, and Di Muzio, Nadia
- Subjects
- *
PROSTATE cancer treatment , *CANCER radiotherapy , *PROSTATECTOMY , *ANDROGEN drugs , *SEMINAL vesicles , *LUTEINIZING hormone releasing hormone derivatives , *RETROSPECTIVE studies - Abstract
Purpose: To retrospectively evaluate the outcome and toxicity in patients receiving high-dose (>69 Gy) adjuvant radiotherapy (HD-ART) and the impact of androgen deprivation therapy (ADT). Methods and Materials: Between 1999 and 2008, 225 node-negative patients were referred for HD-ART with or without ADT to two large academic institutions. Indications for HD-ART were extracapsular extension, seminal vesicle invasion (SVI), and/or positive surgical margins at radical prostatectomy (RP). A dose of at least 69.1 Gy was prescribed to the prostate bed and seminal vesicle bed. The ADT consisted of a luteinizing hormone–releasing hormone analog. The duration and indication of ADT was left at the discretion of the treating physician. The effect of HD-ART and ADT on biochemical (bRFS) and clinical (cRFS) relapse-free survival was examined through univariate and multivariate analysis, with correction for known patient- and treatment-related variables. Interaction terms were introduced to evaluate effect modification. Results: After a median follow-up time of 5 years, the 7-year bRFS and cRFS were 84% and 88%, respectively. On multivariate analysis, the addition of ADT was independently associated with an improved bRFS (hazard ratio [HR] 0.4, p = 0.02) and cRFS (HR 0.2, p = 0.008). Higher Gleason scores and SVI were associated with decreased bRFS and cRFS. A lymphadenectomy at the time of RP independently improved cRFS (HR 0.09, p = 0.009). The 7-year probability of late Grade 2–3 toxicity was 29% and 5% for genitourinary (GU) and gastrointestinal (GI) symptoms, respectively. The absolute incidence of Grade 3 toxicity was <1% and 10% for GI and GU symptoms, respectively. The study is limited by its retrospective design and the lack of a standardized use of ADT. Conclusions: This retrospective study shows significantly improved bRFS and cRFS rates with the addition of ADT to HD-ART, with low Grade 3 gastrointestinal toxicity and 10% Grade 3 genitourinary toxicity. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
14. Improving Positioning in High-Dose Radiotherapy for Prostate Cancer: Safety and Visibility of Frequently Used Gold Fiducial Markers
- Author
-
Fonteyne, Valérie, Ost, Piet, Villeirs, Geert, Oosterlinck, Willem, Impens, Aline, De Gersem, Werner, De Wagter, Carlos, and De Meerleer, Gert
- Subjects
- *
RADIOTHERAPY , *PROSTATE cancer , *PROSTATITIS , *FISHER exact test , *SOFT tissue injuries , *SMOKING , *STATISTICAL correlation - Abstract
Purpose: The use of gold fiducial markers (GFMs) for prostate positioning in high-dose radiotherapy is gaining interest. The purpose of this study was to compare five GFMs regarding feasibility of ultrasound-based implantation in the prostate and intraprostatic lesion (IPL); toxicity; visibility on transabdominal ultrasound (TU) and cone-beam CT (CBCT); reliability of automatic, soft tissue, and GFM-based CBCT patient positioning by comparing manual and automatic fusion CBCT. Methods and Materials: Twenty-five patients were included. Pain and toxicity were scored after implantation and high-dose radiotherapy. Fisher exact test was used to evaluate the correlation of patients’ characteristics and prostatitis. Positioning was evaluated on TU and kilovoltage CBCT images. CBCT fusion was performed automatically (Elekta XVI technology, release 3.5.1 b27, based on grey values) and manually on soft tissue and GFMs. Pearson correlation statistics and Bland-Altman evaluation were used. Five GFMs were compared. Results: Twenty percent of the patients developed prostatitis despite antibiotic prophylaxis. Cigarette smoking was significantly correlated with prostatitis. The visualization of all GFMs on TU was disappointing. Consequently we cannot recommend the use of these GFMs for TU-based prostate positioning. For all GFMs, there was only fair to poor linear correlation between automatic and manual CBCT images, indicating that even when GFMs are used, an operator evaluation is imperative. However, when GFMs were analyzed individually, a moderate to very strong correlation between automatic and manual positioning was found for larger GFMs in all directions. Conclusion: The incidence of prostatitis in our series was high. Further research is imperative to define the ideal preparation protocol preimplantation and to select patients. Automatic fusion is more reliable with larger GFMs at the cost of more scatter. The stability of all GFMs was proven. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
15. High-Dose Salvage Intensity-Modulated Radiotherapy With or Without Androgen Deprivation After Radical Prostatectomy for Rising or Persisting Prostate-Specific Antigen: 5-Year Results
- Author
-
Ost, Piet, Lumen, Nicolaas, Goessaert, An-Sofie, Fonteyne, Valérie, De Troyer, Bart, Jacobs, Filip, and De Meerleer, Gert
- Subjects
- *
PROSTATE cancer treatment , *PROSTATECTOMY , *SALVAGE therapy , *CANCER relapse , *CANCER radiotherapy , *PROSTATE-specific antigen , *ANDROGENS , *CANCER invasiveness - Abstract
Abstract: Background: Long-term results with salvage radiotherapy (SRT) for a biochemical recurrence after radical prostatectomy (RP) are poor. It has been suggested that radiotherapy doses >70Gy might result in improved outcome. Objective: To report on the late toxicity profile and outcome of patients treated with high-dose salvage intensity-modulated radiotherapy (HD-SIMRT) with or without androgen deprivation (AD). Design, setting, and participants: Between 1999 and 2008, 136 patients were referred for HD-SIMRT with or without AD. The median follow-up was 5 yr. Indications for HD-SIMRT were persisting prostate-specific antigen (PSA) or a rising PSA following RP. All patients were irradiated at a single, tertiary, academic centre. AD was initiated on the basis of seminal vesicle invasion, preprostatectomy PSA >20 ng/ml, Gleason score ≥4+3 (n =43), or personal preference of the referring urologist (n =54). Intervention: A median 76-Gy dose was prescribed to the RP bed using intensity-modulated radiotherapy (IMRT) in all patients. AD consisted of a luteinising hormone-releasing hormone analogue for 6 mo. Measurements: Univariate and multivariate analyses were used to examine the influence of patient- and treatment-related factors on late toxicity, biochemical relapse-free survival (bRFS), and clinical relapse-free survival (cRFS). Results and limitations: The 5-yr actuarial bRFS and cRFS were 56% and 86%, respectively. On multivariate analysis, the presence of perineural invasion at RP (hazard ratio [HR]: 6.19, p =0.001) and an increasing pre-SRT PSA (PSA 0.5 ng/ml: HR: 1; PSA 1–1.5 ng/ml: HR: 1.60, p =0.30; and PSA >1 ng/ml: HR: 2.70, p =0.02) were independent factors for a decreased bRFS. The addition of AD improved bRFS (HR: 0.33, p =0.005). On multivariate analysis, none of the variables was a predictor of cRFS. The 5-yr risk of grade 2–3 toxicity was 22% and 8% for genitourinary and gastrointestinal symptoms, respectively. Conclusions: IMRT allows for safe dose escalation to 76Gy with good bRFS. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
16. A Matched Control Analysis of Adjuvant and Salvage High-Dose Postoperative Intensity-Modulated Radiotherapy for Prostate Cancer
- Author
-
Ost, Piet, De Troyer, Bart, Fonteyne, Valérie, Oosterlinck, Willem, and De Meerleer, Gert
- Subjects
- *
ADJUVANT treatment of cancer , *SALVAGE therapy , *POSTOPERATIVE care , *CANCER radiotherapy , *PROSTATE cancer treatment , *PROSTATECTOMY , *CANCER relapse , *MULTIVARIATE analysis , *FOLLOW-up studies (Medicine) - Abstract
Purpose: It is unclear whether immediate adjuvant radiotherapy for high-risk disease at prostatectomy (capsule perforation, seminal vesicle invasion, and/or positive surgical margins) is equivalent to delayed salvage radiotherapy at biochemical recurrence. We performed a matched case analysis comparing high-dose adjuvant intensity modulated radiotherapy (A-IMRT) with salvage IMRT (S-IMRT). Methods and Materials: One hundred forty-four patients with high-risk disease at prostatectomy were referred for A-IMRT, and 134 patients with high-risk disease were referred at biochemical recurrence (rising prostate-specific antigen [PSA], following prostatectomy, above 0.2 ng/ml) for S-IMRT. Patients were matched in a 1:1 ratio according to preoperative PSA level, Gleason score, and pT stage. Median doses of 74 Gy and 76 Gy were prescribed for A-IMRT and S-IMRT, respectively. We report biochemical relapse free survival (bRFS) rates using the Kaplan-Meier method. Univariate and multivariate analyses were used to examine tumour- and treatment-related factors. Results: A total of 178 patients were matched (89:89). From the end of radiotherapy, the median follow-up was 36 months for both groups. The 3-year bRFS rate for the A-IMRT group was 90% compared to 65% for the S-IMRT group (p < 0.05). On multivariate analysis, S-IMRT, Gleason grades of ≥4+3, perineural invasion, preoperative PSA level of ≥10 ng/ml, and omission of androgen deprivation (AD) were independent predictors for a reduced bRFS (p < 0.05). From the date of surgery, the median follow-up was 43 and 60 months for A-IMRT and S-IMRT, respectively. The 3-year bRFS rate for A-IMRT was 91% compared to 79% for S-IMRT (p < 0.05). On multivariate analysis, Gleason grades of ≥4+3, perineural invasion, and omission of AD were independent predictors for a reduced bRFS (p < 0.05). S-IMRT was no longer an independent prognostic factor (p = 0.08). Conclusions: High-dose A-IMRT significantly improves 3-year bRFS compared to S-IMRT. Gleason grades of ≥4+3, perineural invasion, and omission of AD were independent prognostic factors for a decreased bRFS, both from the dates of surgery and from radiotherapy. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
17. Volumetric Arc Therapy and Intensity-Modulated Radiotherapy for Primary Prostate Radiotherapy With Simultaneous Integrated Boost to Intraprostatic Lesion With 6 and 18 MV: A Planning Comparison Study
- Author
-
Ost, Piet, Speleers, Bruno, De Meerleer, Gert, De Neve, Wilfried, Fonteyne, Valérie, Villeirs, Geert, and De Gersem, Werner
- Subjects
- *
ELECTRIC arc , *VOLUMETRIC analysis , *PROSTATE cancer treatment , *COMPARATIVE studies , *MAGNETIC resonance imaging , *PHOTONS , *CANCER radiotherapy - Abstract
Purpose: The aim of the present study was to compare intensity-modulated radiotherapy (IMRT) with volumetric arc therapy (VMAT), in the treatment of prostate cancer with maximal dose escalation to the intraprostatic lesion (IPL), without violating the organ-at-risk constraints. Additionally, the use of 6-MV photons was compared with 18-MV photons for all techniques. Methods and Materials: A total of 12 consecutive prostate cancer patients with an IPL on magnetic resonance imaging were selected for the present study. Plans were made for three IMRT field setups (three, five, and seven fields) and one VMAT field setup (single arc). First, optimal plans were created for every technique using biologic and physical planning aims. Next, an additional escalation to the IPL was planned as high as possible without violating the planning aims of the first step. Results: No interaction between the technique and photon energy (p = .928) occurred. No differences were found between the 6- and 18-MV photon beams, except for a reduction in the number of monitor units needed for 18 MV (p < .05). All techniques, except for three-field IMRT, allowed for dose escalation to a median dose of ≥93 ± 6 Gy (mean ± standard deviation) to the IPL. VMAT was superior to IMRT for rectal volumes receiving 20–50 Gy (p < .05). Conclusion: VMAT allowed for dose escalation to the IPL with better sparing of the rectum than static three-, five-, and seven-field IMRT setups. High-energy photons had no advantage over low-energy photons. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
18. Analysis of Prostate Bed Motion Using Daily Cone-Beam Computed Tomography During Postprostatectomy Radiotherapy
- Author
-
Ost, Piet, De Meerleer, Gert, De Gersem, Werner, Impens, Aline, and De Neve, Wilfried
- Subjects
- *
PROSTATE cancer treatment , *CANCER radiotherapy , *RADIOTHERAPY , *POSTURE , *CANCER tomography , *RETROSPECTIVE studies , *PELVIC bones , *MEDICAL errors - Abstract
Purpose: To report on the interfraction total positioning error of the postoperative prostate bed and to quantify its components (bony misalignment [BM] and prostate bed motion [PBM]) using daily kilovoltage cone-beam computed tomography (CBCT). The role of an adaptive radiotherapy schedule (ART) was investigated. Methods and Materials: A total of 547 daily CBCT images from 15 consecutive patients who had been treated with prostate bed radiotherapy were retrospectively analyzed. The positioning error was measured by rigid co-registration of the daily CBCT with pretreatment CT planning scan. The total positioning error was quantified by co-registration of the CBCT with the CT planning scan to match the anterior rectal wall. Automatic bony pelvis co-registration was performed to separate BM and PBM. The ART was determined by the average total positioning error from the first 5 CBCT images. Results: The systematic error for the total positioning error in the left–right, superoinferior, and anteroposterior direction was 2.69, 2.00, and 2.65 mm with a random error of 1.99, 1.49, and 2.25 mm, resulting in a planning target volume margin of 8, 6, and 8 mm, respectively. ART reduced the margin by 54%, 44%, and 40%, respectively. Systematic errors in the left–right, superoinferior, and anteroposterior direction for BM was 2.66, 1.83, and 2.60 mm and for PBM was 0.44, 0.92, and 2.50 mm with a random error of 1.88, 1.24, and 1.77 mm for BM and 0.99, 1.38, and 2.32 mm for PBM, respectively. Conclusion: Without treatment verifications, 6–8-mm planning target volume margins are required because of PBM and BM. The anteroposterior PBM was significant. An ART protocol can reduce these planning target volume margins. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Adjuvant High-Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: Clinical Results in 104 Patients
- Author
-
Ost, Piet, Fonteyne, Valérie, Villeirs, Geert, Lumen, Nicolaas, Oosterlinck, Willem, and De Meerleer, Gert
- Subjects
- *
CANCER radiotherapy complications , *DOSE-effect relationship in pharmacology , *PROSTATE cancer , *PROSTATE surgery , *PROSTATECTOMY , *CANCER patients , *ADJUVANT treatment of cancer , *PROSTATE-specific antigen , *SURGICAL site - Abstract
Abstract: Background: Approximately 25% of patients treated with adjuvant radiotherapy (RT) will develop a biochemical failure within 5 yr after RT when doses of 60–64 Gray (Gy) are used. Objective: To report on the safety and biochemical outcome of adjuvant intensity-modulated RT (IMRT) with doses >70Gy. Design, setting, and participants: Between 1999 and 2008, 104 patients underwent radical prostatectomy (RP) followed by adjuvant IMRT with or without androgen deprivation (AD) with a median follow-up of 36 mo. Indications for adjuvant IMRT were capsule perforation, seminal vesicle invasion (SVI) and/or positive surgical margins at prostatectomy specimen. All patients were irradiated at a single tertiary academic centre. AD was initiated on the basis of SVI, a preprostatectomy prostate-specific antigen level >20ng/ml, Gleason score ≥4+3 (n =36), or personal preference of the referring urologist (n =32). Intervention: A median dose of 74Gy was prescribed to the planning target volume using IMRT in all patients. AD consisted out of a luteinising hormone-releasing hormone analogue for 6 mo. Measurements: We report on acute and late toxicity, biochemical relapse–free survival (bRFS), and clinical progression. The Kaplan-Meier method was used to estimate bRFS. Univariate analysis was used to examine the influence of patient- and treatment-related factors on bRFS. Results and limitations: With respect to acute toxicity, no patients developed grade 3 gastrointestinal (GI) toxicity, and eight patients developed grade 3 genitourinary (GU) toxicity (8%). With respect to late toxicity, no patients developed grade 3 GI toxicity, and four patients (4%) developed grade 3 GU toxicity. A urethral stricture was observed in six patients (6%). The 3- and 5-yr actuarial bRFS was 93%. On univariate analysis, bRFS rates were worse when SVI (p <0.02), Gleason score ≥4+3 (p <0.02), or negative surgical margins (p <0.02) were present. AD did not influence bRFS. Six patients had a clinical relapse. Conclusions: Adjuvant high-dose IMRT after prostatectomy is safe and bRFS is excellent. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
20. Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732–9
- Author
-
De Bleser, Elise and Ost, Piet
- Subjects
- *
CASTRATION-resistant prostate cancer , *STEREOTACTIC radiotherapy , *PROSTATE cancer , *RADIOTHERAPY - Published
- 2020
- Full Text
- View/download PDF
21. Re: Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
- Author
-
Hadaschik, Boris and Ost, Piet
- Subjects
- *
CASTRATION-resistant prostate cancer , *PROSTATE cancer , *CLINICAL trials - Published
- 2019
- Full Text
- View/download PDF
22. Re: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.
- Author
-
De Man, Kathia and Ost, Piet
- Subjects
- *
CASTRATION-resistant prostate cancer , *PROSTATE - Published
- 2019
- Full Text
- View/download PDF
23. Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers.
- Author
-
Fonteyne, Valerie and Ost, Piet
- Subjects
- *
PROSTATE cancer treatment , *COMBINED modality therapy , *DOCETAXEL - Published
- 2019
- Full Text
- View/download PDF
24. It Ain’t Over Till the Fat Lady Sings: The POPSTAR Trial.
- Author
-
Ost, Piet
- Subjects
- *
PROSTATE cancer treatment , *METASTASIS , *STEREOTACTIC radiotherapy , *PROSTATE-specific antigen , *BONE metastasis , *CANCER relapse , *CANCER treatment - Published
- 2018
- Full Text
- View/download PDF
25. Is 68Ga-Prostate-specific Membrane Antigen–ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?
- Author
-
Chandrasekar, Thenappan, Ost, Piet, and Tilki, Derya
- Subjects
- *
PROSTATE cancer patients , *CANCER relapse , *POSITRON emission tomography , *COMPUTED tomography , *ANTIGENS - Published
- 2018
- Full Text
- View/download PDF
26. Editorial Comment.
- Author
-
Poelaert, Filip, Ost, Piet, and Lumen, Nicolaas
- Published
- 2017
- Full Text
- View/download PDF
27. 3125: Cold liver metastases according to a CD8 radiomic-score : a new target for SBRT with immunotherapy?
- Author
-
Sun, Roger, Hecht, Markus, Robert, Caroline, Routier, Emilie, Gaipl, Udo S., Frey, Benjamin, Bahleda, Rastilav, Robert, Charlotte, Ost, Piet, and Deutsch, Eric
- Subjects
- *
CD8 antigen , *IMMUNOTHERAPY - Published
- 2024
- Full Text
- View/download PDF
28. 277: Adjuvant EBRT for muscle-invasive bladder cancer: phase 2 trial secondary analysis (NCT02397434).
- Author
-
Verghote, Flor, Dirix, Piet, Van Praet, Charles, Berghen, Charlien, Vanneste, Ben, Junius, Sara, Liefhooghe, Nick, Noé, Leen, De Meerleer, Gert, Ost, Piet, and Fonteyne, Valérie
- Subjects
- *
CANCER invasiveness , *BLADDER cancer , *SECONDARY analysis - Published
- 2024
- Full Text
- View/download PDF
29. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?
- Author
-
Sanmamed, Noelia, Gómez-Rivas, Juan, Buchser, David, Montijano, Miguel, Gómez-Aparicio, María Antonia, Duque-Santana, Victor, Torres, Lisselott, Zilli, Thomas, Ost, Piet, Maldonado, Antonio, López-Campos, Fernando, and Couñago, Felipe
- Subjects
- *
ANDROGEN receptors , *DOCETAXEL , *PROSTATE cancer , *OVERALL survival , *RANDOMIZED controlled trials - Abstract
In recent years, several systemic therapies have been introduced for metastatic hormone-sensitive prostate cancer, including androgen deprivation therapy (ADT) combined with docetaxel (Doc) and/or new-generation androgen receptor signaling inhibitors (ARSI). Trials evaluating ADT + ARSI have consistently demonstrated an overall survival (OS) benefit for doublet therapy over ADT alone. Similarly, the STOPCaP meta-analysis showed an OS benefit in favor of ADT + Doc versus ADT alone. ARSI, Doc, and ADT have different antitumor mechanisms, thus potentiating the effect of combination therapy. Two randomized trials showed that the addition of ARSI to ADT + Doc improves OS, especially for synchronous high-volume disease. However, the real question about triplet therapy remains unanswered: whether combining Doc with ARSI improves outcomes compared to ADT + ARSI. As there are no head-to-head comparisons, this narrative review aims to summarize the current evidence regarding triplet therapy versus doublet therapy including ADT + ARSI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
- Author
-
Miszczyk, Marcin, Rajwa, Pawel, Yanagisawa, Takafumi, Nowicka, Zuzanna, Shim, Sung Ryul, Laukhtina, Ekaterina, Kawada, Tatsushi, von Deimling, Markus, Pradere, Benjamin, Rivas, Juan Gómez, Gandaglia, Giorgio, van den Bergh, Roderick C.N., Goldner, Gregor, Supiot, Stephane, Zilli, Thomas, Trinh, Quoc-Dien, Nguyen, Paul L., Briganti, Alberto, Ost, Piet, and Ploussard, Guillaume
- Subjects
- *
PROSTATE cancer patients , *ANDROGEN deprivation therapy , *CLINICAL trials , *LONGITUDINAL method , *SCIENCE databases - Abstract
Metastasis-directed therapy results in promising clinical outcomes and low rates of adverse events. It can be a valuable treatment option either for oligorecurrent patients wishing to avoid androgen deprivation therapy or as a treatment intensification method. Phase 3 trials are necessary. Despite the lack of level 1 evidence, metastasis-directed therapy (MDT) is used widely in the management of metastatic prostate cancer (mPCa) patients. Data are continuously emerging from well-designed prospective studies. To summarise and report the evidence on oncological and safety outcomes of MDT in the management of mPCa patients. We searched the PubMed, Scopus, and Web of Science databases for prospective studies assessing progression-free survival (PFS), local control (LC), androgen deprivation therapy (ADT)-free survival (ADT-FS), overall survival (OS), and/or adverse events (AEs) in mPCa patients treated with MDT. A meta-analysis was performed for 1- and 2-yr PFS, LC, ADT-FS, OS, and rate of AEs. Meta-regression and sensitivity analysis were performed to account for heterogeneity and identify moderators. We identified 22 prospective studies (n = 1137), including two randomised controlled trials (n = 116). Two studies were excluded from the meta-analysis (n = 120). The estimated 2-yr PFS was 46% (95% confidence interval [CI]: 36–56%) or 42% (95% CI: 33–52%) after excluding studies using biochemical or ADT-related endpoints. The estimated 2-yr LC, ADT-FS, and OS were 97% (95% CI: 94–98%), 55% (95% CI: 44–65%), and 97% (95% CI: 95–98%), respectively. Rates of treatment-related grade 2 and ≥3 AEs were 2.4% (95% CI: 0.2–7%) and 0.3% (95% CI: 0–1%), respectively. MDT is a promising treatment strategy associated with favourable PFS, excellent LC, and a low toxicity profile that allows oligorecurrent hormone-sensitive patients to avoid or defer ADT-related toxicity. Integration of MDT with other therapies offers a promising research direction, in particular, in conjunction with systemic treatments and as a component of definitive care for oligometastatic PCa. However, in the absence of randomised trials, using MDT for treatment intensification remains an experimental approach, and the impact on OS is uncertain. Direct treatment of metastases is a promising option for selected prostate cancer patients. It can delay hormone therapy and is being investigated as a way of intensifying treatment at the expense of manageable toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Reply from Authors re: Vincent Khoo. Is There Another Bite of the Cherry? The Case for Radical Local Therapy for Oligometastatic Disease in Prostate Cancer. Eur Urol 2016;69:13–4: Oligometastatic Prostate Cancer: More Than Just Cherry-picking?
- Author
-
Jereczek-Fossa, Barbara Alicja, Ost, Piet, and De Meerleer, Gert
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *PROSTATE cancer patients , *CLINICAL trials , *DISEASE prevalence , *PROSTATE cancer treatment - Published
- 2016
- Full Text
- View/download PDF
32. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature.
- Author
-
Villeirs, Lauren, Tailly, Thomas, Ost, Piet, Waterloos, Marjan, Decaestecker, Karel, Fonteyne, Valerie, Van Praet, Charles, and Lumen, Nicolaas
- Subjects
- *
HYPERBARIC oxygenation , *RADIOTHERAPY , *INTERSTITIAL cystitis , *CYSTITIS , *META-analysis - Abstract
The present study assessed the efficacy of hyperbaric oxygen therapy in reducing symptoms of radiation cystitis, a specific type of iatrogenic injury to the bladder, by systematic review of recent literature. The MEDLINE, Embase and Web of Science databases were searched using combinations of the terms "radiation," "cystitis" and "hyperbaric oxygen" to identify articles evaluating patients with radiation cystitis, treated with hyperbaric oxygen therapy. Only recent (≤10 years) original studies were included. Data were extracted and pooled in order to calculate descriptive weighted averages. Articles were evaluated on their level of evidence. A total of 20 papers were obtained, resulting in a cohort of 815 patients who were treated with hyperbaric oxygen therapy for radiation cystitis. Overall and complete response rates varied from 64.8% to 100% and 20% to 100%, respectively. The weighted average overall and complete response rates were 87.3% and 65.3%, respectively. Adverse events were observed in 9.6% of the patients, but permanent side‐effects were rare. The most prominent limitations were high cost and low availability. Hyperbaric oxygen therapy is effective in the treatment of radiation‐induced cystitis, with minimal adverse events, but low availability and high cost. At present, evidence is low; therefore, more prospective studies are required. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Stereotactic body radiation therapy after radical prostatectomy: current status and future directions.
- Author
-
Le Guevelou, Jennifer, Magne, Nicolas, Counago, Felipe, Magsanoc, Juan Martin, Vermeille, Matthieu, De Crevoisier, Renaud, Benziane-Ouaritini, Nicolas, Ost, Piet, Niazi, Tamim, Supiot, Stéphane, and Sargos, Paul
- Subjects
- *
STEREOTACTIC radiotherapy , *RADICAL prostatectomy , *RADIOTHERAPY , *ANDROGEN deprivation therapy , *PROSTATE cancer - Abstract
Purpose: Around 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy (RP). The aim of this review is to describe both toxicity and oncological outcomes following stereotactic body radiation therapy (SBRT) delivered to the prostate bed (PB). Method: In april 2023, we performed a systematic review of studies published in MEDLINE or ClinicalTrials.gov according to Preferred Reporting Items for Systematic Reviews, using the keywords "stereotactic radiotherapy" AND "postoperative" AND "prostate cancer". Results: A total of 14 studies assessing either adjuvant or salvage SBRT to the whole PB or macroscopic local recurrence (MLR) within the PB, and SBRT on radiorecurrent MLR within the PB were included. Doses delivered to either whole PB or MLR between 30 to 40 Gy are associated with a low rate of late grade ≥ 2 genitourinary (GU) toxicity, ranging from 2.2 to 15.1%. Doses above 40 Gy are associated with increased rate of late GU toxicity, raising up to 38%. Oncological outcomes should be interpreted with caution, due to both short follow-up, heterogeneous populations and androgen deprivation therapy (ADT) use. Conclusion: PB or MLR SBRT delivered at doses up to 40 Gy appears safe with relatively low late severe GU toxicity rates. Caution is needed with dose-escalated RT schedules above 40 Gy. Further prospective trials are eagerly awaited in this disease setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Salvage radiotherapy: A plea for dose-escalation with intensity-modulated radiotherapy
- Author
-
Ost, Piet, Cozzarini, Cesare, Bossi, Alberto, and Meerleer, Gert De
- Subjects
- *
PROSTATE tumors - Published
- 2012
- Full Text
- View/download PDF
35. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21–30.
- Author
-
Ost, Piet and Ghadjar, Pirus
- Subjects
- *
PROSTATE cancer treatment , *PROSTATE surgery , *CANCER radiotherapy , *SYSTEMATIC reviews , *META-analysis , *PROSTATE cancer patients - Published
- 2016
- Full Text
- View/download PDF
36. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. Eur Urol 2014;65:1058–66.
- Author
-
Ost, Piet, Briganti, Alberto, and Giannarini, Gianluca
- Published
- 2014
- Full Text
- View/download PDF
37. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
- Author
-
Saesen, Robbe, Van Hemelrijck, Mieke, Bogaerts, Jan, Booth, Christopher M., Cornelissen, Jan J., Dekker, Andre, Eisenhauer, Elizabeth A., Freitas, André, Gronchi, Alessandro, Hernán, Miguel A., Hulstaert, Frank, Ost, Piet, Szturz, Petr, Verkooijen, Helena M., Weller, Michael, Wilson, Roger, Lacombe, Denis, and van der Graaf, Winette T.
- Subjects
- *
TUMOR treatment , *RESEARCH methodology , *CLINICAL medicine research , *INDIVIDUALIZED medicine , *DATABASE management , *ONCOLOGY , *MEDICAL research - Abstract
The emergence of the precision medicine paradigm in oncology has led to increasing interest in the integration of real-world data (RWD) into cancer clinical research. As sources of real-world evidence (RWE), such data could potentially help address the uncertainties that surround the adoption of novel anticancer therapies into the clinic following their investigation in clinical trials. At present, RWE-generating studies which investigate antitumour interventions seem to primarily focus on collecting and analysing observational RWD, typically forgoing the use of randomisation despite its methodological benefits. This is appropriate in situations where randomised controlled trials (RCTs) are not feasible and non-randomised RWD analyses can offer valuable insights. Nevertheless, depending on how they are designed, RCTs have the potential to produce strong and actionable RWE themselves. The choice of which methodology to employ for RWD studies should be guided by the nature of the research question they are intended to answer. Here, we attempt to define some of the questions that do not necessarily require the conduct of RCTs. Moreover, we outline the strategy of the European Organisation for Research and Treatment of Cancer (EORTC) to contribute to the generation of robust and high-quality RWE by prioritising the execution of pragmatic trials and studies set up according to the trials-within-cohorts approach. If treatment allocation cannot be left up to random chance due to practical or ethical concerns, the EORTC will consider undertaking observational RWD research based on the target trial principle. New EORTC-sponsored RCTs may also feature concurrent prospective cohorts composed of off-trial patients. • The role of real-world data (RWD) in cancer clinical research is increasing. • A false dichotomy exists between RWD studies and randomised controlled trials (RCTs). • There are different methodologies for RWD studies, including RCT designs. • The methodology to be employed should be determined by the research question. • We outline the RWD strategy of a large academic clinical cancer research organisation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
- Author
-
Bukavina, Laura, Luckenbaugh, Amy N., Hofman, Michael S., Hope, Tom, Kamran, Sophia C., Murphy, Declan G., Yamoah, Kosj, and Ost, Piet
- Subjects
- *
PROSTATE cancer , *POSITRON emission tomography , *CLINICAL trials , *LITERATURE reviews , *DRUG target , *DIAGNOSIS - Abstract
Studies suggest that prostate-specific membrane antigen (PSMA)-targeted imaging is superior to conventional imaging for detection of primary and recurrent prostate cancer, albeit with several clinically relevant limitations. PSMA-targeted imaging may have greater sensitivity and specificity for detection of oligometastatic disease. However, whether PSMA imaging alters disease progression despite treatment intensification is yet to be determined in prospective clinical trials. Prostate-specific membrane antigen (PSMA) is a promising molecular target for prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to PCA in the primary and recurrent settings. To summarize available data and recommendations regarding the use of PSMA in newly diagnosed and recurrent PCa via a narrative review. A literature review was conducted using MEDLINE (via PubMed) and Scopus. The search strategy included meta-analyses, reviews, and original studies on staging and restaging with 68Ga-PSMA positron emission tomography (PET)/computed tomography (CT). Studies comparing PSMA-targeted imaging and conventional imaging suggest superior performance of PSMA-targeted imaging in primary and recurrent PCa, albeit with several clinically relevant limitations. Pretreatment 68Ga-PSMA PET/CT allowed more accurate PCa staging in compared to routine practice for high-risk cases, and identified a number of otherwise unknown metastatic lesions. In biochemically recurrent PCa, PSMA PET can reveal sites of recurrence with greater sensitivity and specificity than conventional imaging, potentially detecting a major proportion of occult disease. This review will help providers in applying the most up-to-date and relevant literature to (1) determine which patients truly have oligometastatic disease and (2) ascertain who is most likely to experience a meaningful response to local consolidation in the biochemical recurrence setting. Data on PSMA diagnostic studies in primary and recurrent PCa highlight the accuracy and clinical application of PSMA PET. While this review and the evidence to date might lead to a perception of superiority in metastasis directed therapy, fundamental lack of phase III clinical trials with clinically meaningful outcomes are yet to be determined. PSMA (prostate-specific membrane antigen) scans have shown great promise for initial evaluation of prostate cancer (PCa) and in detection of PCa recurrence. The benefits are more apparent for initial staging of PCa. There are more limited clinical trial results for PCa recurrence on how best to use this new technique to guide cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy.
- Author
-
Mercier, Carole, Strijbos, Michiel, and Ost, Piet
- Subjects
- *
STEREOTACTIC radiotherapy , *RENAL cell carcinoma - Published
- 2022
- Full Text
- View/download PDF
40. The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients.
- Author
-
Van Hemelryk, Annelies, De Meerleer, Gert, Ost, Piet, Poelaert, Filip, De Gersem, Werner, Decaestecker, Karel, De Visschere, Pieter, and Fonteyne, Valérie
- Subjects
- *
PROSTATE cancer patients , *PROSTATE cancer treatment , *RADIOTHERAPY , *PROSTATE diseases , *TOXICITY testing , *ANTIANDROGENS , *PROSTATE tumors treatment , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PROSTATE tumors , *RADIATION injuries , *RESEARCH , *STATISTICAL sampling , *SURVIVAL , *TUMOR classification , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CASE-control method , *THERAPEUTICS - Abstract
Purpose: Improved outcome is reported after surgery or external beam radiation therapy (EBRT) plus androgen deprivation therapy (ADT) for patients with lymph node (LN) positive (N1) prostate cancer (PC). Surgical series have shown that pathologic (p)N1 PC does not behave the same in all patients. The aim of this study was to perform a matched-case analysis to compare the outcome of pN1 and pN0 PC after high-dose EBRT plus ADT.Methods and Materials: Radiation therapy up to 80 Gy was delivered to the prostate with a minimal dose of 45 Gy to the pelvis for pN1 patients. After matching, Kaplan-Meier statistics were used to compare the 5-year biochemical and clinical relapse-free survival (bRFS and cRFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Acute and late rectal and urinary toxicity was evaluated.Results: Sixty-nine pN1 PC patients were matched 1:1 with pN0 PC patients. The median follow-up time was 60 months. The 5-year bRFS and cRFS for pN1 versus pN0 PC patients were 65% ± 7% versus 79% ± 5% (P=.08) and 70% ± 6% versus 83% ± 5% (P=.04) respectively. No significant difference was found in bRFS or cRFS rates between low volume pN1 (≤2 positive LNs) and pN0 patients. The 5-year PCSS and OS were comparable between pN1 and pN0 PC patients: PCSS: 92% ± 4% versus 93% ± 3% (P=.66); OS: 82% ± 5% versus 80% ± 5% (P=.58). Severe toxicity was rare for both groups, although pN1 patients experienced significantly more acute grade 2 rectal toxicity.Conclusion: Primary EBRT plus 2 to 3 years of ADT is a legitimate treatment option for pN1 PC patients, especially those with ≤2 positive LNs, and this with bRFS and cRFS rates comparable to those in pN0 PC patients. For pN1 PC patients with >2 positive LNs, bRFS and cRFS are worse than in pN0 patients, but even in this subgroup, long-term disease control is obtained. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Delineation of the Postprostatectomy Prostate Bed Using Computed Tomography: Interobserver Variability Following the EORTC Delineation Guidelines
- Author
-
Ost, Piet, De Meerleer, Gert, Vercauteren, Tom, De Gersem, Werner, Veldeman, Liv, Vandecasteele, Katrien, Fonteyne, Valérie, and Villeirs, Geert
- Subjects
- *
PROSTATECTOMY , *TOMOGRAPHY , *GUIDELINES , *CANCER radiotherapy , *STANDARD deviations , *STATISTICS , *PROSTATE cancer treatment - Abstract
Purpose: The present study aims to assess the interobserver agreement of prostate bed delineation after radical prostatectomy using CT alone as proposed by the European Organization for Research and Treatment of Cancer (EORTC) guidelines. Methods and Materials: Six observers delineated the postoperative prostate bed (PB) and the original seminal vesicle position or remnants (SV) of 10 patients according to the EORTC guidelines. Contours were then compared for agreement between observers (the apparent volume overlap and generalized kappa statistics). Standard deviations were also calculated to measure the variability of the position of the outer margins. Results: The mean volume of 100% agreement (±1 standard deviation, SD) was only 5.0 (±3.3) ml for the PB and 0.9 (±1.5) ml for the SV, whereas the mean union of all contours (±1 SD) was 41.1 (±11.8) ml and 25.3 (±13.4) ml, respectively. The mean overall agreement corrected for chance was moderate for both the PB (mean kappa, 0.49; range, 0.35–0.62) and SV (mean kappa, 0.42; range, 0.22–0.59). The overall SD of the outer margins of the PB ranged from 4.6 to 7.0 mm Conclusion: The delineation of the postprostatectomy bed using CT shows only a moderate observer agreement when following the EORTC guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. Eur Urol 2010;57:622–30
- Author
-
Ost, Piet, Bossi, Alberto, and De Meerleer, Gert
- Published
- 2010
- Full Text
- View/download PDF
43. Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: In Regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996–1001)
- Author
-
Ost, Piet, Fonteyne, Valérie, De Neve, Wilfried, De Gersem, Werner, De Wagter, Carlos, Vandecasteele, Katrien, Duprez, Fréderic, and De Meerleer, Gert
- Published
- 2009
- Full Text
- View/download PDF
44. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?
- Author
-
Glicksman, Rachel M., Palma, David A., Deek, Matthew P., Tsai, C Jillian, Chmura, Steve, Siva, Shankar, Ost, Piet, Tran, Phuoc T., and Berlin, Alejandro
- Subjects
- *
STEREOTACTIC radiotherapy , *RADIOSURGERY - Published
- 2022
- Full Text
- View/download PDF
45. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
- Author
-
De Man, Kathia, Van Laeken, Nick, Schelfhout, Vanessa, Fendler, Wolfgang P., Lambert, Bieke, Kersemans, Ken, Piron, Sarah, Lumen, Nicolaas, Decaestecker, Karel, Fonteyne, Valérie, Delrue, Louke, De Vos, Filip, and Ost, Piet
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *CANCER relapse , *CROSSOVER trials , *PROSTATE cancer - Abstract
The radiotracer 18F-PSMA-11 has been proved to be noninferior to 68Ga-PSMA-11 for the detection and staging of prostate cancer in primary and recurrent settings. This tracer can therefore be used as a cost-efficient alternative. Fluorine-18 (18F)-labelled prostate-specific membrane antigen (PSMA) offers several advantages over gallium-68 (68Ga) in terms of costs, yield, transport/distribution, and image resolution. This trial investigates the new radiotracer 18F-PSMA-11 via a prospective, intraindividual crossover design. The trial was powered for noninferiority of 18F-PSMA-11 over 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in terms of the number of positive PET scans. Secondary endpoints were as follows: (1) superiority of 18F-PSMA-11 over 68Ga-PSMA-11 with respect to the number of positive PET scans, the total number of suspicious prostate cancer lesions, and the miPSMA expression score of corresponding lesions; (2) correlation of the PET/CT images with available follow-up data for 18F-PSMA-11 and 68Ga-PSMA-11; and (3) assessment of the interobserver variability. Prostate cancer patients (primary or biochemical recurrence) were randomised in a double-blind crossover design whereby each patient received both 18F-PSMA-11 and 68Ga-PSMA-11 PET/CT. All scans were reviewed and scored by three independent experienced nuclear physicians following the proposed guideline for the interpretation of PSMA-ligand PET/CT, as described by Eiber et al. In total, 82 patients were included for scan analyses. The primary endpoint was met: per patient, the proportions of positive scans rated by the three readers were 67%/67%, 65%/65%, and 73%/70% for 18F-PSMA-11/68Ga-PSMA-11 PET/CT. The miPSMA expression score was higher for 18F-PSMA-11 than for 68Ga-PSMA-11 for the reference reader. Follow-up data showed identical estimated sensitivity for both the 18F-PSMA-11 and the 68Ga-PSMA-11 scan (0.92, 0.83, and 0.92 for the three readers). A fair to good agreement among readers (at patient level) was obtained, which was demonstrated by a Light's kappa value of 0.59 for both tracers. The tracer 18F-PSMA-11 is noninferior to 68Ga-PSMA-11. Superiority of 18F-PSMA-11 was limited to the miPSMA expression score, given by the reference reader. Inter-rater agreement was fair to good, and equal for both radiotracers. In this study, we compared two radiotracers: 18F-PSMA-11 and 68Ga-PSMA-11. We proved that 18F-PSMA-11 is not inferior to 68Ga-PSMA-11 for detecting prostate cancer and thus can be used as an alternative. Possible superiority of this tracer should be further investigated in specific subpopulations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging: 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.
- Author
-
De Man, Kathia, Piron, Sarah, Van Laeken, Nick, Delrue, Louke, Fonteyne, Valérie, Lumen, Nicolaas, Van den Broeck, Bliede, Kersemans, Ken, Ost, Piet, and Schelfhout, Vanessa
- Subjects
- *
POSITRON emission tomography computed tomography , *MAGNETIC resonance imaging , *SYSTEMIC family therapy , *HISTOLOGY , *QUESTIONNAIRES - Abstract
Purpose: In this study, we evaluated the impact of 18F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed. Procedures: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the 18F-PSMA-11 findings. Results: The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on 18F-PSMA-11 PET/CT. Conclusion: 18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis.
- Author
-
Barry, Aisling S., Helou, Joelle, Bezjak, Andrea, Wong, Rebecca, Dawson, Laura A., Ringash, Jolie, Fazelzad, Rouhi, Liu, Zhihui, Olson, Robert, Palma, David, Ost, Piet, Siva, Shankar, Phillips, Ryan, and Adhikari, Neill K.J.
- Subjects
- *
STEREOTACTIC radiotherapy , *QUALITY of life , *CLINICAL trials - Abstract
• Reported health-related quality of life (HRQOL) outcomes are lacking in patients with oligo-metastatic disease (OMD) • Little is known of the impact of metastatic directed therapies, such as stereotactic body radiotherapy (SBRT), on short and long-term HRQOL. • SBRT does not appear to adversely affect HRQOL over time in patients with OMD. • More robust assessment and reporting of HRQOL in studies of OMD is needed. Published health-related quality of life (HRQOL) outcomes are lacking in patients treated for oligo-metastatic disease (OMD). The aim of this systematic review and individual patient data meta-analysis is to determine the effect of stereotactic body radiotherapy (SBRT) on HRQOL outcomes of patients with OMD. Studies screened included adults with extra-cranial OMD, defined as ≤ 5 metastases, SBRT intended as definitive treatment, and HRQOL as primary or secondary outcome. Primary outcome was change in HRQOL at 12-months from baseline in patients with OMD who received SBRT (versus not), reported as standardized mean difference (SMD). A total of 7556 publications were identified, four studies met inclusion criteria (2 single arm interventional studies and 2 randomised controlled trials [RCTs]), and individual patient data was available from 3 studies (175 patients). In the two RCTs, there was no SS difference in the SMD between patients who received SBRT and those that did not (0.09 [95 % CI −0.32, 0.5], P = 0.66). On meta-analysis of patients (N = 107) who received SBRT the SMD was −0.23 (95 % CI [−0.42, −0.04], versus −0.25 (95 % CI [−0.57, 0.07]) in those who did not (N = 37) receive SBRT, demonstrating a small deterioration from baseline. In patients with OMD, there is no difference in HRQOL at 12-months from baseline between patients who received SBRT and those that did not. However, a small HRQOL deterioration was found in both groups of patients. More in-depth analysis of relevant HRQOL domains, in the setting of OMD, is required to better understand the potential impact of SBRT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
- Author
-
Fonteyne, Valérie, Sadeghi, Simin, Ost, Piet, Vanpachtenbeke, Frank, Vuye, Philippe, Lumen, Nicolaas, and De Meerleer, Gert
- Subjects
- *
ACADEMIC medical centers , *CHI-squared test , *FISHER exact test , *PROSTATE tumors , *RADIATION doses , *RADIOTHERAPY , *RECTUM , *SURVIVAL analysis (Biometry) , *URINARY organs , *DISEASE incidence , *DATA analysis software , *DESCRIPTIVE statistics , *KRUSKAL-Wallis Test - Abstract
Background. External beam radiotherapy is an excellent treatment for patients with prostate cancer (PC). Assessing long-term radiotherapy-induced toxicity is important. We evaluated the impact of implementing different rectal dose volume constraints (DVC) on late rectal and urinary toxicity. Material and methods. Six hundred and thirty-seven PC patients were treated with high-dose intensity-modulated radiotherapy (IMRT) in the primary (median dose of 78 Gy to the prostate) or postoperative setting [median dose of 74 (adjuvant) and 76 Gy (salvage) to the prostatic bed]. Three groups were defined according to different DVC applied over time. The incidence of late rectal and urinary toxicity was evaluated. Three-year actuarial risk estimations of grade 2-3 rectal and urinary toxicity were calculated (Kaplan-Meier statistics). Results. Median follow-up was five years. Overall, the incidence of late grade 3 and 2 rectal toxicity was 1% and 11%. The calculated three-year actuarial risk of developing late grade ≥ 2 rectal toxicity decreased from 16% to 7% and 5% for patients in Group 1, Group 2 and Group 3, respectively (p < 0.001). Respectively, 17 (4%) and 98 (24%) patients developed grade 3 and 2 late urinary toxicity in the primary setting. In the postoperative setting, 15 (6%) and 62 (26%) patients developed grade 3 and 2 urinary toxicity, respectively. The three-year actuarial risk of developing late ≥ grade 2 urinary toxicity in primary- and postoperative-treated patients was 22% and 23%, respectively. This was not significantly different between the three groups. Conclusion. The majority of patients developed no or only moderate rectal toxicity after high-dose IMRT for PC. Implementing different rectal DVC resulted in a significant decrease of late rectal toxicity without affecting urinary toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
49. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
- Author
-
Buelens, Sarah, Poelaert, Filip, Claeys, Tom, De Bleser, Elise, Dhondt, Bert, Verla, Wesley, Ost, Piet, Rappe, Bernard, De Troyer, Bart, Verbaeys, Caroline, Kimpe, Bart, Billiet, Ignace, Plancke, Hendrik, Fransis, Karen, Willemen, Patrick, Ameye, Filip, Decaestecker, Karel, and Lumen, Nicolaas
- Subjects
- *
PROSTATECTOMY , *METASTASIS , *RADICAL prostatectomy , *PROSTATE cancer , *ASYMPTOMATIC patients , *LONGITUDINAL method - Abstract
Objectives: To investigate the role of cytoreductive radical prostatectomy in addition to standard of care for patients with newly diagnosed metastatic prostate cancer. Materials and Methods: This multicentre, prospective study included asymptomatic patients from 2014 to 2018 (NCT02138721). Cytoreductive radical prostatectomy was offered to all fit patients with resectable tumours, resulting in 40 patients. Standard of care was administered to 40 patients who were ineligible or unwilling to undergo surgery. The primary endpoint was castration resistant cancer‐free survival at the time point of ≥50% events. The secondary endpoint was local event‐free survival. Kaplan–Meier and Cox regression analyses with propensity‐score analysis were applied. Results: After a median (quartiles) follow‐up of 35 (24–47) months, 42 patients became castration‐resistant or died. The median castration resistant cancer‐free survival was 53 (95% confidence interval [CI] 14–92) vs 21 (95% CI 15–27) months for cytoreductive radical prostatectomy compared to standard of care (P = 0.017). The 3‐year estimates for local event‐free survival were 83% (95% CI 71–95) vs 59% (95% CI 51–67) for cytoreductive radical prostatectomy compared to standard of care (P = 0.012). However, treatment group showed no significance in the multivariable models for castration resistant cancer‐free survival (P = 0.5) or local event‐free survival (P = 0.3), adjusted for propensity‐score analysis. Complications were similar to the non‐metastatic setting. Patients undergoing surgery were younger, with lower baseline prostate‐specific antigen levels, alkaline phosphatase levels and metastatic burden. Conclusion: The present LoMP study was unable to show a difference between the two inclusion groups regarding castration resistant cancer‐free survival for asymptomatic patients with newly diagnosed metastatic prostate cancer. These results validate previous evidence that, in well‐selected and informed patients, cytoreductive radical prostatectomy is feasible and safe, with corresponding continence rates compared to the non‐metastatic, high‐risk setting. Whether cytoreductive radical prostatectomy could be a valuable option to achieve good local palliation needs to be further researched. Overall, the role of cytoreductive radical prostatectomy needs to be further explored in randomized studies to correct for potential bias. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.
- Author
-
Fonseca, Nicolette M., Van der Eecken, Kim, Herberts, Cameron, Verbeke, Sofie, Ng, Sarah W.S., Lumen, Nicolaas, Ritch, Elie, Murtha, Andrew J., Bernales, Cecily Q., Schönlau, Elena, Moris, Lisa, Van Dorpe, Jo, Annala, Matti, Wyatt, Alexander W., and Ost, Piet
- Subjects
- *
PROSTATE cancer , *CASTRATION-resistant prostate cancer , *POSITRON emission tomography computed tomography , *CIRCULATING tumor DNA - Abstract
Knowledge Generated We found that some lung-recurrent metastatic hormone-sensitive prostate cancer has very good clinical outcomes and that lung metastases in these patients lack driver gene alterations associated with aggressive disease including defects in TP53, RB1, or DNA damage repair genes. Localized prostate cancer is treated with surgery or radiation, but 20%-40% of patients experience disease relapse indicated by rising serum prostate-specific antigen (PSA).[1],[2] In recent years, the use of new functional imaging techniques has demonstrated that most patients harbor clinical metastases within lymph nodes or bone at the time of PSA (ie, biochemical) recurrence.[3],[4] Current guidelines for metastatic hormone-sensitive prostate cancer (mHSPC) recommend systemic androgen deprivation therapy (ADT) plus androgen receptor (AR) pathway inhibitors and/or taxane-based chemotherapy.[5] [7] However, patient outcomes are highly variable, and we need to improve disease segmentation and customize treatment plans. Our cohort was also not enriched for DNA damage repair gene alterations, as previously reported in a series of 16 patients with lung-only mHSPC and germline and/or somatic profiling.[11] However, this published series included patients with de novo metastatic presentation and family history of prostate cancer, so is a different population to unselected lung-recurrent mHSPC. However, subgroup analyses of clinical trials in late-stage hormone-resistant prostate cancer suggest that lung metastases may be associated with different clinical outcomes to liver or other patterns of spread.[8],[9] There is limited and retrospective support for this hypothesis in treatment-naive mHSPC,[10] [13] as studies are difficult to perform because of the relative rarity of lung metastases. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.